DIA.CHEMILUX SARS-CoV-2 ACE2/RBD Neutralization – CLIA
Chemi-Luminescence ImmunoAssay (CLIA) for the serological determination of the neutralization activity of antibodies to SARS-CoV-2, induced by natural infection and/or vaccination, able to block the interaction of Receptor Binding Domain (RBD) and ACE2 and thus the virus infection.
The assay is intended for testing sera and plasma collected from:
(a) PCR-negative Covid-19 individuals successfully recovered from infection, to assure presence of anti RBD neutralizing antibodies;
(b) human donors, recovered from COVID-19 infection, positive for anti-RBD antibodies for the generation of hyperimmune plasma, as a possible immunotherapeutic approach to the disease;
(c) vaccinated individuals to assure a reliable and efficient immunization with development of neutralizing antibodies able to block ACE2-RBD binding.